Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked faithfully but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire job interview that I came away with a poor viewpoint of the business.

Irony of irony, the poor opinion of mine of the company has grown steadily, yet the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology as well as associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) plus the first brand new drug application approval ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and numerous therapies, it’s this individual therapy in addition to a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very start of the interest of mine in this particular business. Judging by way of the multiples of thousands of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *